Gastroresistant capsular device prepared by injection molding by L. Zema et al.
Graphical Abstract (for review)
GASTRORESISTANT CAPSULAR DEVICE PREPARED BY INJECTION MOLDING 
Lucia Zema, Giulia Loreti, Alice Melocchi, Alessandra Maroni, Luca Palugan, Andrea Gazzaniga* 
Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, via G. Colombo 71 20133 Milano, 
Italy 
 5 
*Corresponding author (A. Gazzaniga) phone: +39 2 50324654; fax: +39 2 50324658 
e-mail address: andrea.gazzaniga@unimi.it 
 
*Manuscript
Click here to view linked References
Abstract  10 
 
In the present work, the possibility of manufacturing by Injection Molding (IM) a gastro-resistant capsular 
device based on hydroxypropyl methyl cellulose acetate succinate (HPMCAS) was investigated. By 
performing as an enteric soluble container, such a device may provide a basis for the development of 
advantageous alternatives to coated dosage forms. Preliminarily, the processability of the selected 15 
thermoplastic polymer was evaluated, and the need for a plasticizer (polyethylene glycol 1500) in order to 
counterbalance the glassy nature of the molded items was assessed. However, some critical issues related to 
the physical/mechanical stability (shrinkage and warpage) and opening time of the device after the pH 
change were highlighted. Accordingly, an in-depth formulation study was carried out taking into account 
differing release modifiers potentially useful for enhancing the dissolution/disintegration rate of the capsular 20 





 CLV could be manufactured, and a promising performance was achieved with 
appropriate gastric resistance in pH 1.2 medium and break-up in pH 6.8 within 1 h. These results would 
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1. Introduction 
Preventing the chemical degradation of active principles in the acidic environment of the stomach and 
protecting the gastric mucosa from irritation phenomena induced by drug assumption are the two main 
reasons for conceiving gastro-resistant dosage forms (Dulin, 2010). Such formulations are also used to 35 
pursue selective release into particular regions of the intestinal tract, either to exploit favorable absorption 
sites or provide treatment for local diseases. Moreover, according to a time-dependent strategy, the colon can 
be targeted by enteric-coated pulsatile delivery systems able to provide lag phases starting on gastric 
emptying, with the coating dissolution, and lasting throughout the small intestinal transit time (SITT) (Davis, 
1985; Gazzaniga et al., 1994; Gazzaniga et al., 2006). 40 
Gastric resistance is generally obtained by means of polymers with pH-dependent solubility; the most widely 
employed are acrylic and metacrylic acid copolymers (e.g. Eudragit L, S and FS), polyvinyl acetate phthalate 
(PVAP) and cellulose derivatives (e.g. cellulose acetate phthalate, CAP; hydroxypropyl methyl cellulose 
acetate succinate, HPMCAS) (McGinity and Felton, 2008). These are applied onto drug-containing solid 
cores (tablets, capsules, pellets, granules) using different techniques that can basically be distinguished 45 
according to the amount of solvent required, preferably water, and the role it would play in the coating 
process. Large amounts of liquid to be dried are in fact involved in the deposition of gastro-resistant layers 
from polymeric solutions or suspensions (film-coating technique) (Bianchini et al., 1991; Felton et al., 1995; 
Nastuzzi et al., 2000; Siepmann et al., 2006). On the other hand, in order to avoid the use of water thus 
overcoming stability issues and drawbacks associated with the need for solvent removal, dry-coating 50 
techniques were proposed, such as conventional compaction-based processes (press-coating technique) 
(Cerea et al., 2008a; Blubaugh et al., 1958; Fukui et al., 2001a; Fukui et al., 2001b). More sophisticated 
approaches envisage the deposition onto core substrates of liquid (non-aqueous) or solid (powder blends) 
coating agents, and subsequent formation of a continuous layer by solidification/polymerization or heat-
curing (Lau and Gleason, 2007; Obara et al., 1999; Kablitz et al., 2006; Cerea et al., 2008b). Despite the 55 
improvements in terms of process time, manufacturing costs and stability of the final product, the industrial 
scale-up and availability of suitable coat-forming agents still represent major limitations to a wider diffusion 
of dry-coating techniques. 
In the case of enteric-coated products intended to release the active ingredient as soon as they are emptied 
from the stomach, a rapid disintegration/dissolution of the coating layer is expected. This is especially 60 
important when drugs having an absorption window in the upper part of the small intestine are dealt with 
(Liu and Basit, 2010). It was recently highlighted that gastro-resistant systems can take up to 2 hours for a 
complete exposure of the core to the intestinal fluids, thus potentially affecting the drug bioavailability and 
the efficacy of the therapy (McConnell et al., 2008). 
In coating processes an important role is generally played by the drug-containing core, the physical (shape, 65 
dimension, surface), technological (thermal resistance, hardness, friability, wettability, 
disintegration/dissolution tendency) and stability characteristics of which may constrain or even impair each 
of the above-mentioned techniques (Felton and McGinity, 1996; Cole et al., 2002; Felton and McGinity, 
2003; Porter and Felton, 2010). 
Based on the above-discussed premises, the possibility of preparing container-like enteric-soluble devices 70 
that could be filled and sealed after manufacturing would represent an innovative and advantageous 
alternative to the design of coated gastro-resistant dosage forms. In this respect, hollow HPMCAS or PVAP 
pipes were prepared by hot-melt extrusion, manually filled with a model drug powder and heat-sealed at their 
open ends, thus providing enteric devices that showed promising results (Mehuys et al., 2005). 
Injection molding (IM), which involves the injection of appropriately softened/melted materials into a mold 75 
wherein they are given a definite three-dimensional shape, was proven a viable technique in the preparation 
of capsular items composed of separately-manufactured parts to be matched after filling with various 
formulations (powders, granules/pellets, semi-solids or liquids) through well-established processes (Zema et 
al., 2012). The performance of such devices would depend on their composition and design features 
(morphology and thickness of the shell) only, in spite of differing characteristics of the conveyed drug and/or 80 
formulation, which could offer major benefits in terms of time and costs required for development. 
Moreover, they would be ready-to-use, i.e. easy to be filled for extemporaneous preparations. Molded 
capsular shells composed of potato starch (Capill
®
) were proposed to replace commercial gelatin or HPMC 
capsules intended for immediate release (IR) (Eith et al., 1986; Vilivalam et al., 2000). More recently, IM 
was successfully employed to prepare a capsular pulsatile delivery device based on swellable/erodible 85 
polymers (hydroxypropyl cellulose, HPC) (Gazzaniga et al., 2011a; Gazzaniga et al., 2011b; Gazzaniga et 
al., 2011c). 
In the present work, the feasibility of IM in the preparation of HPMCAS-based capsules was explored with 
the aim of developing a gastro-resistant shell to be used as an innovative delivery platform for enteric dosage 
forms. 90 
 
2 Materials and Methods 
2.1 Materials 
Hydroxypropyl methyl cellulose acetate succinate (HPMCAS, AQUOT-LG
®
; Shin-Etsu, Japan), 
polyethylene glycol (PEG 1500; Clariant Masterbatches, Italy), sodium starch glycolate (Explotab
®
 CLV; 95 
JRS, Germany) (d10 = 10 μm; d50 = 25 μm; d90 = 52 μm), polyvinyl alcohol-polyethylene glycol graft 
copolymer (Kollicoat
®
 IR; BASF, Germany) (d10 = 9 μm; d50 = 23 μm; d90 = 55 μm), dipotassium hydrogen 
phosphate anhydrous (K2HPO4; Carlo Erba, Italy) (d10 = 2 μm; d50 = 6 μm; d90 = 24 μm), sodium hydrogen 
carbonate (NaHCO3; Carlo Erba, Italy) (d10 = 15 μm; d50 = 28 μm; d90 = 63 μm), acetaminophen (Atabay, 




2.2.1 IM process 
IM was performed by a bench-top micromolding machine (BabyPlast 6/10P, Cronoplast S.L.; Rambaldi 105 
S.r.l., Italy). 
The polymeric formulations were prepared by co-grinding HPMCAS and PEG 1500 in a blade mill; blends 
containing release modifiers were obtained by mixing in turbula (Type T2C, WAB, Switzerland) for 20 min. 
Prior to use, all materials except for PEG 1500 were kept in a ventilated oven at 40 °C for 24 h. In Table 1 
the composition (% by weight) of the molded polymeric formulations is reported. 110 
Before processing, the behavior of the polymer and polymeric formulations when subjected to heating or IM 
was evaluated as follows. 
Hot-plate experiment. 2-3 g of polymer/polymeric formulation were placed in an aluminum pan on a hot 
plate and heated under continuous manual mixing, while gradually increasing the temperature up to 200 °C. 
Samples were checked for overall aspect, color, texture and mechanical characteristics during heating and 115 
after cooling. 
Air shot test. 50 g of polymer/polymeric formulation were loaded into the IM press through the hopper and 
expelled from the injecting unit as during a purge operation (Rosato et al., 2000). The test was repeated 
under different operating temperatures. Samples were checked for overall aspect, color and mechanical 
characteristics immediately after ejection and when solidified. 120 
2.2.1.1 Manufacturing of molded items 
50 g of polymeric formulation were loaded into the plasticating chamber of the IM press through the hopper 
and then conveyed by means of a first piston to the injecting chamber. By successively applying two distinct 
pressures, each for a defined period of time and at a selected rate, another piston (10 mm diameter) injected a 
specific amount of melt (charge) through a 1 mm diameter nozzle into the mold cavity (disk or capsular 125 
shape). Prior to product ejection, the mold was kept closed by applying a closing pressure to allow the 
injected melt to cool down and harden. The rate of each process stage was expressed as % of the maximum 
value. 
Molded items were prepared by means of two different molds: i) a 30 mm diameter disk-shaped mold 
provided with a central gate, enabling the selection of differing thicknesses (200, 400, and 600 μm) and ii) a 130 
capsular mold with two cavities for the cap (8 mm height and 8 mm diameter) and the body (11 mm height 
and 8 mm diameter), respectively, each provided with a lateral gate, enabling the preparation of matching 
items within a single manufacturing cycle and the selection of differing shell thicknesses (300, 600, and 900 
μm) (Gazzaniga et al., 2011b). The operating conditions were varied within different ranges of values 
according to whether disks or capsules were employed (Table 2). Molds were manually lubricated with 135 





2.2.2 Characterization of molded items 
Molded items, i.e. disks and assembled capsule shells, were checked for weight (analytical balance BP211, 
Sartorius, Germany; n= 10) and thickness (digimatic indicator ID-C112X, Mitutoyo, Japan; n=10). Digital 
photographs (Nikon D70, Nikon, Japan) of molded items were acquired, and photomicrographs were taken 
by scanning electron microscope (SEM; Sigma, Zeiss, Germany) after gold sputtering (10 nm). The 145 
characterization was performed immediately after ejection, except for photomicrographs, and after 24 hours 
storage at ambient conditions (24 ± 2°C/55 ± 5 % RH). Photomicrographs of a few molded disks were also 
collected after incubation in unstirred pH 6.8 phosphate buffer at room temperature for 120 min and drying 
in a ventilated oven at 40 °C for 24 h. 
2.2.2.1 Evaluation of gastric resistance performance 150 
Disks. Immediately after ejection disks were positioned on manually-assembled cells modified from the 
extraction cells used in the dissolution test for transdermal patches (Ph. Eur. 7) (Figure 1). The reservoir 
compartment was loaded with an amount of a powder tracer (acetaminophen) ranging from 43 to 48 mg. The 
surface exposed to the acceptor fluid was 177 mm
2
. The test (n = 3) was performed in pharmacopoeial 
apparatus 2 (Dissolution System 2100B, Distek, New Jersey) at 100 rpm under the conditions of the 155 
Dissolution test for delayed-release dosage forms (Method B, USP 34) except for the medium volume (600 
mL). Fluid samples were withdrawn at fixed time points and assayed spectrophotometrically at 254 nm 
(spectrophotometer lambda25, Perkin Elmer, Massachusetts). 
Capsular devices. Each capsule body was manually filled with an amount of a powder tracer 
(acetaminophen) ranging from 86 to 92 mg and closed with a matching cap. The gastric resistance 160 
performance (n = 3) was evaluated in pharmacopoeial apparatus 2 (Dissolution System 2100B, Distek, New 
Jersey) at 100 rpm under the conditions of the Dissolution test for delayed-release dosage forms (Method B, 
USP 34). Fluid samples were withdrawn and assayed as above reported. Lag time (t10%), i.e. the time to 10 % 
release in pH 6.8 phosphate buffer, was calculated from the release curves (n=3) and reported as a detail in 
the figures together with the relevant coefficient of variation (CV). 165 
 
3. Results and discussion 
With the aim of developing a new injection-molded capsule-like container for enteric release, the relevant 
design and formulation features needed to preliminarily be assessed. The latter were indeed expected to 
fulfill a number of different requirements, such as the suitability for the oral route, versatility in terms of 170 
contents and possibility of filling through established industrial encapsulation processes. At the same time, 
the desired gastric resistance performance followed by a rapid disintegration/dissolution at intestinal pH 
values had to be ensured and merely depend upon the container device irrespective of the conveyed 
formulation. Furthermore, the IM process should have been feasible and yield molded items with appropriate 
aspect, technological properties and physical/mechanical stability. As in the micromolding (µIM) technique, 175 
which is currently applied to the production of medical devices and miniaturized electronic parts, a specially-
devised press had to be employed, and the manufacturing was expected to be particularly critical in view of 
the need for meeting strictly-controlled geometric as well as functional characteristics and maintain them 
over the shelf-life of the final formulation (Hoyle, 2010; Gomes et al., 2011; Zhang et al., 2012; Heckele and 
Schomburg, 2004; Giboz et al., 2007; Koç and Özel, 2011). Besides, a strong impact of the operating 180 
pressure and thermal history of the material on the dimensional stability of the molded item had to be taken 
into account. 
HPMCAS was chosen as the barrier-forming polymer because of its wide application as an enteric coating 
material and thermoplastic properties that were already exploited for hot-melt extrusion (HME) (Mehuys et 
al., 2005). Preliminarily, its softening/melting behavior following heating on hot plate or injection processing 185 
(air shot test) and its characteristics after solidification were evaluated, indicating the need for the addition of 
a plasticizer in order to counteract the glassy nature of the molded material. Among various plasticizers 
tested (triethyl citrate; dibuthyl sebacate; PEG 400, 1500, 6000 and 20000), PEG 1500 was selected based on 
the homogeneous aspect of the softened/molten raw materials and the improved mechanical characteristics of 
the solidified composite. Moreover, HPMCAS blends with PEG 1500 turned out to be the most easily 190 
porcessed by the IM press in use. The influence of the plasticizer on the processability of the polymeric 
formulation and the characteristics of the product was investigated in the 15-35 % (with respect to the 
amount of polymer) range by means of two differing molds, i.e. a disk- and a capsule-shaped one, each 
allowing the nominal thickness of molded items to be varied within a relatively wide range (600, 400 and 
200 µm or 900, 600 and 300 µm, respectively). The former allows the production of centrally-gated circular 195 
disks (diameter 30 mm) especially suitable for the evaluation of dimensional changes. With respect to the 
capsule-shaped mold, though offering several advantages (i.e. production of capsule cap and body within the 
same cycle, possibility of varying the shell thickness), some limitations in the characteristics of the resulting 
items could be expected in view of the lateral position of the gate and presence of a mobile insert 
determining the width of the cavity (Gazzaniga et al., 2011b). 200 
The amount of 15 % of plasticizer turned out to be insufficient, not only on account of the poor flexibility 
shown by the molded items, but also because only 600 µm thick disks could be obtained and no capsular 
shells at all. Increasing the PEG 1500 content to 25 % was already enough to easily manufacture disks up to 
200 µm thickness and complete capsular shells of 900 µm. Only with the highest amount of plasticizer 
tested, 600 µm capsules could be prepared. 205 
When thermoplastics are processed by IM, the dimensions of the molded part change as the part cools. 
Often, these changes are referred to as either shrinkage or warpage and can be used to predict the appropriate 
mold geometry (Fisher, 2003). Although shrinkage is based on thermal contraction, other mechanisms may 
be responsible for dimensional changes after demolding (e.g. inherent stresses, crystallization, mechanical 
constraint). For example, if residual stresses created by variations in the cooling rate are strong enough to 210 
overcome the relevant structural integrity, the part will warp upon ejection from the mold. The control of 
shrinkage is particularly important in applications requiring tight tolerances. The wall thickness was shown 
to have a major influence on shrinkage that generally turns out increased for thicker parts, because of the 
variation in a series of parameters such as the holding pressure or the cooling and crystallization rates. In 
table 3, differences between the thickness of disks and the width of the relevant mold cavity (600 µm) are 215 
reported along with digital photographs of the molded items immediately after ejection (t = 0) and over time 
(t = 3 and 24 h). 
Molded HPMCAS disks were proven to increase in thickness immediately after demolding, and no 
significant influence (p < 0.1) of the amount of plasticizer on this parameter was found. On the contrary, a 
warp tendency of molded disks was noticed that could be related to the amount of plasticizer in the 220 
formulation. In fact, only for the items containing 15 % of PEG 1500, bending was neither observed 
following demolding nor after storage. This allowed thickness measurements to be performed also 24 h after 
manufacturing. 
As far as the gastric resistance of PEG25 and PEG35 formulations is concerned, the relevant capsular 
devices, irrespective of the shell thickness, remained intact in acidic fluid (pH = 1.2) but they were unable to 225 
release their contents within 2 h in phosphate buffer pH 6.8. 
These results pointed out some critical issues with respect to the goal of developing a delivery platform for 
enteric dosage forms based on HPMCAS capsules. In particular, the shrinkage/warpage tendency of the 
polymeric formulation and the need to shorten the opening time of the device had both to be taken into 
account. In the plastics industry, the set-up of the melt composition, design of the final mold and adjustment 230 
of the operating conditions would have concomitantly be performed (Figure 2). However, because of the 
inherent complexity of this approach, a formulation study was undertaken at this stage, and molded 
prototypes were used as screening tools for assessing the effectiveness of the gastric resistance performance. 
In order to enhance the dissolution/disintegration rate of the capsular device at intestinal pH values, i) release 
modifiers, the channelling action of which could be attributed to the inherent solubility or swelling 235 
properties, and ii) buffering salts (dipotassium hydrogen phosphate and sodium hydrogen carbonate), 
potentially suitable for increasing the microenvironmental pH of the surrounding fluids, were considered. 
The addition of soluble pore formers or disintegrants (e.g. polyvinylpyrrolidone and croscarmellose sodium, 
respectively) to film-coating suspensions of pH-responsive polymers was already suggested with the aim of 
improving the pulsatile release of drugs to the ileo-colonic region (Zhang et al., 2007; Schellekens et al., 240 
2008). Moreover, a double-coated enteric system consisting of an inner layer of Eudragit
®
 L or S neutralized 
with organic acids and an outer conventional coating of the same polymer was recently proposed (Liu et al., 
2009; Liu and Basit, 2010; Liu et al., 2010). Such a device was subject to a fast and consistent disintegration 
after stomach emptying (around 30 min in vivo disintegration time). 
The types and/or amounts of adjuvants were selected by preliminary heating and/or molding tests. In this 245 
respect, browning phenomena occurred at operating temperatures on polymeric samples containing either the 
phosphate or carbonate salt, thus pointing out possible stability issues for molded items. A polyvinyl alcohol-
polyethylene glycol graft copolymer (Kollicoat
®
 IR), generally employed as the film-forming polymer for 
immediate-release coated dosage forms or as a binder in fast-dissolving tablets, was selected as the soluble 
pore former. Although characterized by a glassy-rubbery transition temperature (Tg) around 200 °C, when 250 
Kollicoat
®
 IR was worked in admixture with plasticized HPMCAS, a homogeneous molded material was 
obtained already at the lowest operating temperatures. Among the disintegrants tested (starch and cellulose 
derivatives), sodium starch glycolate (Explotab
®
 CLV) was shown to exert no negative impact on the 
processability of the polymeric substrate and rather improve the dimensional stability of molded items as 
expected from solid fillers (Zweifel et al., 2009). As far as the polymer/plasticizer ratio in the polymeric 255 
formulations with the release modifiers is concerned, 25 % of PEG 1500 with respect to the amount of 
HPMCAS was preferred because of the acceptable balance between processability of the polymeric substrate 
and dimensional changes of the product that was previously obtained. 
Disks of 200,400 and 600 µm containing 30 % by weight of either the soluble pore former or the disintegrant 
selected were obtained, whereas in no case intact and complete capsular shells with thickness other than 900 260 
µm were produced. The manufacturing of 200 µm disks with the KIR formulation was especially critical, 
thus providing brittle and often damaged items that could not withstand characterization. SEM 
photomicrographs helped highlight the surface and structure characteristics of molded items containing 
Kollicoat
®
 IR or Explotab
®
 CLV as compared with HPMCAS ones (Figure 3). In particular, solid particles 
distributed throughout the cross-section of the disintegrant-containing item are clearly evident. 265 
In Figure 4 the release profiles of capsular devices containing a powder tracer and the relevant t10% values in 
pH 6.8 buffer are reported. 
Both the Kollicoat
®
 IR- and Explotab
®
 CLV-based capsular systems were demonstrated able to withstand the 
acidic medium (pH 1.2) for two hours, confirming that the release modifiers were efficiently embedded in 
the molded polymeric matrix. In pH 6.8 buffer a lag time of about 1,5 h prior to the break-up of capsular 270 
devices and release of the conveyed powder was observed, which was slighlty shorter for the disintegrant-
containing shell. Indeed, a minor diffusive release phase was shown by the capsular system with the soluble 
pore former. In order to evaluate the influence of the polymeric barrier thickness, the molded disks made of 
HPMCAS blends with Kollicoat
®
 IR and Explotab
®
 CLV were used. For this purpose, a testing method 
analogous to the compendial dissolution test for transdermal patches was set up. The amount of tracer 275 
assayed in the acceptor fluid, which was separated from the donor powder reservoir by molded disks of 
differing thicknesses (Figure 1), was plotted versus time (Figure 5). As in the release profiles of capsules, a 
lag time prior to the rupture of the polymeric barrier was observed. Only in the case of the EXP formulation, 
t10% values showed a tendency to decrease when reducing the thickness of disks to 200 µm. Indeed, a small 
amount of tracer was recovered in the acidic medium when one of the 200 µm disks was tested thus pointing 280 
out the possible existence of a thickness threshold for gastric resistance failure. The polymeric barrier 
containing Kollicoat
®
 IR confirmed a less prompt break-up, with an initial diffusive release phase. Moreover, 
in the case of 400 µm disks, t10% values obtained from the disintegrant-containing formulation were 
significantly (p < 0.1) lower as compared with those relevant to the KIR one, thus indicating that a more 
efficient mechanism would promote the polymer disintegration/dissolution in pH 6.8 buffer. The overall 285 
results obtained from capsular devices and disks containing pore formers indicated that the erosion of the 
HPMCAS matrix would in any case be triggered by the pH change, as this allows the medium to reach the 
adjuvants incorporated. Afterwards, the soluble polymer Kollicoat
®
 IR may aid the solvent penetration only, 
while the disintegrant could also promote the formation of cracks in the polymeric barrier thereby reducing 
its resistance to rupture (Schellekens et al., 2008). The latter hypothesis was confirmed by photomicrographs 290 
of partially eroded molded items (i.e. disks exposed to pH 6.8 buffer for 120 minutes and dried before being 
analysed) (Figure 6). In fact, the disintegrant particles embedded in the polymeric matrix seem to be located 
within hollows that are larger than the dried particle itself and show tears on their edges. Such hollows and 
relevant tears may have formed because of the swelling of Explotab
®
 CLV upon exposure to the aqueous 
fluid. 295 
According to the above discussed mechanisms, the ability of the soluble pore former to increase the extent of 
solvent penetration could improve the efficiency of the disintegrant. In this respect, confirmatory results 
were preliminarily obtained comparing the performance of 900 µm thick capsular shells containing blends of 
Kollicoat
®
 IR and Explotab
®
 CLV (10 % and 20 %, respectively, and vice versa) (Figure 7) with that of 
shells based on a single component (Kollicoat
®
 IR or Explotab
®
 CLV). Indeed, devices prepared from the 300 
2EXP1KIR formulation in which 10 % of the disintegrant was replaced with the soluble polymer showed the 
shortest lag time. On the contrary, only 10 % of disintegrant in the shell composition seemed not enough to 
establish the cracking mechanism. 
In order to undertake the development of gastric resistant container-like devices, the impact of the shell 
thickness on the release performance needed to be more in depth investigated. Therefore, some attempts 305 
were made at improving the IM processability of adjuvant-containing HPMCAS formulations. As expected, 
by adjusting the polymer to plasticizer ratio (increasing the amount of PEG 1500 to 35 % on dry polymer), 
600 µm capsular shells were manufactured containing 30 % of Explotab
®
 CLV. The relevant devices showed 
adequate gastric resistance in the acidic medium and a lag phase of less than 1 h in pH 6.8 buffer (Figure 8). 
Thus, the possibility of obtaining an earlier break-up of enteric capsule-like devices by decreasing the shell 310 
thickness was confirmed, and this could represent the proper approach to the achievement of the desired 
release behavior.  
 
4. Conclusions 
The use of capsular containers suitable for conveying different types of drug formulations and determining 315 
the relevant release performance was recently proposed; for the manufacturing of such devices, IM technique 
was exploited because of the advantages it would offer in terms of versatility (dimensions, composition and 
shape or shape details), scalability and patentability of the relevant products. In this work, the development 
of enteric soluble capsules based on HPMCAS was approached. The feasibility of the manufacturing process 
with a polymeric formulation containing a plasticizer and a release modifier or mixtures of different types of 320 
release modifiers (a soluble pore former and a disintegrant, i.e. Kollicoat
®
 IR and Explotab
®
 CLV, 
respectively) was assessed. This basic composition showed promising results with respect to a possible fine 
tuning of the thickness and mechanical characteristics of the capsule shell, thus allowing the gastric 
resistance performance to be defined. Accordingly, the development process would be worth being pursued 








Bianchini, R., Resciniti, M., Vecchio, C., 1991. Technological evaluation of aqueous enteric coating systems 
with and without insoluble additives. Drug Dev. Ind. Pharm. 17, 1779-1794. 
Blubaugh, F.C., Zapapas, J.R., Sparks, M.C., 1958. An enteric compression coating. I. In vitro studies. J. 335 
Am. Pharm. Assoc. 47, 857-862. 
Cerea, M., Foppoli, A., Maroni, A., Palugan, L., Zema, L., Sangalli, M.E., 2008b. Dry coating of soft 
gelatine capsules with HPMCAS. Drug Dev. Ind. Pharm. 34, 1196-1200. 
Cerea, M., Zema, L., Palugan, L., Gazzaniga, A., 2008a. Recent developments in dry coating. Pharm. Tech. 
Eur. 20, 40-44. 340 
Cole, E.T., Scott, R.A., Connor, A.L., Wilding, I.R., Petereit, H.-U., Schminke, C., Beckert, T., Cadé, D., 
2002. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int. J. Pharm. 231, 83-95. 
Davis, S.S., 1985. The design and evaluation of controlled release systems for the gastro-intestinal tract. J. 
Control. Release 2, 27-38. 
Dulin, W., 2010. Oral targeted drug delivery systems: enteric coating, in: Wen, H., Park, K. (Eds.), Oral 345 
controlled release formulation design and drug delivery: theory to practice. John Wiley & Sons, New Jersey, 
pp. 205-224. 
Eith, L., Stepto, R.F.T., Tomka, I., Wittwer, F., 1986. The injection-moulded capsule. Drug Dev. Ind. Pharm. 
12, 2113-2126. 
Felton, L.A., Haase, M.M., Shah, N.H., Zhang, G., Infeld, M.H., Malick, A.W., McGinity, J.W., 1995. 350 
Physical and enteric properties of soft gelatin capsules coated with Eudragit
®
 L 30 D-55. Int. J. Pharm. 113, 
17-24. 
Felton, L.A., McGinity, J.W., 1996. The influence of tablet hardness and tablet hydrophobicity on the 
adhesive properties of an acrylic resin copolymer. Pharm. Dev. Technol. 1, 381-389. 
Felton, L.A., McGinity, J.W., 2003. Enteric film coating of soft gelatin capsules. Drug Deliv. Tech. 3, 48-51. 355 
Fischer, J.M., 2003. Handbook of molded part shrinkage and warpage. William Andrew Inc., New York. 
Fukui, E., Miyamura, N., Kobayashi, M., 2001a. Effect of magnesium stearate or calcium stearate as 
additives on dissolution profiles of diltiazem hydrochloride from press-coated tablets with 
hydroxypropylmethylcellulose acetate succinate in the outer shell. Int. J. Pharm. 216, 137-146. 
Fukui, E., Miyamura, N., Yoneyama, T., Kobayashi, M., 2001b. Drug release from and mechanical 360 
properties of press-coated tablets with hydroxypropylmethylcellulose acetate succinate and plasticizers in the 
outer shell. Int. J. Pharm. 217, 33-43. 
Gazzaniga, A., Cerea, M., Cozzi, A., Foppoli, A., Maroni, A., Zema, L., 2011b. A novel injection-molded 
capsular device for oral pulsatile delivery based on swellable/erodible polymers. AAPS Pharm. Sci. Tech. 
12, 295-303. 365 
Gazzaniga, A., Cerea, M., Cozzi, A., Foppoli, A., Tavella, G., Zema, L., 2011a. Pharmaceutical dosage 
forms for time-specific drug delivery. EP 2317988. 
Gazzaniga, A., Foppoli, A., Maroni, A., Cozzi, A., Macchi, E., Cerea, M., 2011c. Injection-molded capsular 
device for oral pulsatile delivery: an in vivo evaluation. 38
th
 CRS annual meeting & exposition July 30 - 
August 3, National Harbor, Maryland. 370 
Gazzaniga, A., Giordano, F., Sangalli, M.E., Zema, L., 1994. Oral colon-specific drug delivery: design 
strategies. STP Pharma Pratiques 4, 336-343. 
Gazzaniga, A., Maroni, A., Sangalli, M.E., Zema, L., 2006. Time-controlled oral delivery systems for colon 
targeting. Expert Opin. Drug Deliv. 3, 583-597. 
Giboz, J., Copponnex, T., Mèle, P., 2007. Microinjection molding of thermoplastic polymers: a review. J. 375 
Micromech. Microeng. 17, R96-R109. 
Gomes, M.E., Ribeiro, A.S., Malafaya, P.B., Reis, R.L., Cunha, A.M., 2011. A new approach based on 
injection moulding to produce biodegradable starch-based polymeric scaffolds: morphology, mechanical and 
degradation behavior. Biomaterials 22, 883-889. 
Heckele, M., Schomburg, W.K., 2004. Review on micro molding of thermoplastic polymers. J. Micromech. 380 
Microeng. 14, R1-R14. 
Hoyle, R., 2010. Manufacturing components for a micro litre drug delivery system. Eur. Med. Device. 
Technol. 1. 
Kablitz, C.D., Harder, K., Urbanetz, N.A., 2006. Dry coating in a rotary fluid bed. Eur. J. Pharm. Sci. 27, 
212-219. 385 
Koç, M., Özel, T. (Eds.) 2011. Micro-manufacturing: design and manufacturing of micro-products. John 
Wiley & Sons publication, New Jersey. 
Lau, K.K.S., Gleason, K.K., 2007. All-dry synthesis and coating of methacrylic acid copolymers for 
controlled release. Macromol. Biosci. 7, 429-434. 
Liu, F., Basit, A.W., 2010. A paradigm shift in enteric coating: achieving rapid release in the proximal small 390 
intestine of man. J. Control. Release 147, 242-245. 
Liu, F., Lizio, R., Meier, C., Petereit, H.-U., Blakey, P., Basit, A.W., 2009. A novel concept in enteric 
coating: a double-coating system providing rapid drug release in the proximal small intestine. J. Control. 
Release 133, 119-124. 
Liu, F., Morenoa, P., Basit, A.W, 2010. A novel double-coating approach for improved pH-triggered 395 
delivery to the ileo-colonic region of the gastrointestinal tract. Eur. J. Pharm. Biopharm. 74, 311-315. 
McConnell, E.L., Fadda, H.M., Basit, A.W., 2008. Gut instincts: explorations in intestinal physiology and 
drug delivery. Int. J. Pharm. 364, 213-226. 
McGinity, J.W., Felton, L.A., (Eds.) 2008. Aqueous polymeric coatings for pharmaceutical dosage forms, 
third ed., Informa Healthcare, New York. 400 
Mehuys, E., Remon, J.-P., Vervaet, C., 2005. Production of enteric capsules by means of hot-melt extrusion. 
Eur. J. Pharm. Sci. 24, 207-212. 
Nastruzzi, C., Cortesi, R., Esposito, E., Genovesi, A., Spadoni, A., Vecchio, C., Menegatti, E., 2000. 
Influence of formulation and process parameters on pellet production by powder layering technique. AAPS 
Pharm. Sci. Tech. 1, E9. 405 
Obara, S., Maruyama, N., Nishiyama, Y., Kokubo, H., 1999. Dry coating: an innovative enteric coating 
method using a cellulose derivative. Eur. J. Pharm. Biopharm. 47, 51-59. 
Porter, S.C., Felton, L.A., 2010. Techniques to assess film coatings and evaluate film-coated products. Drug 
Dev. Ind. Pharm. 36, 128-142. 
Rosato, D.V., Rosato, D.V., Rosato, M.G., 2000. Injection Molding Handbook, third ed., Kluwer Academic 410 
Publishers, Massachussets. 
Schellekens, R.C.A., Stellaard, F., Mitrovic, D., Stuurman, F.E., Kosterink, J.G.W., Frijlink, H.W., 2008. 
Pulsatile drug delivery to ileo-colonic segments by structured incorporation of disintegrants in pH-responsive 
polymer coatings. J. Control. Release 132, 91-98. 
Siepmann, F., Siepmann, J., Walther, M., MacRae, R., Bodmeier, R., 2006. Aqueous HPMC-AS coatings: 415 
effect on formulation and processing parameters on drug release and mass transport mechanism. Eur. J. 
Pharm. Biopharm. 63, 262-269. 
Vilivalam, V.D., Illum, L., Iqbal, K., 2000. Starch capsules: an alternative system for oral drug delivery. 
Pharm. Sci. Technol. Today 3, 64-69. 
Zema, L., Loreti, G., Melocchi, A., Maroni, A., Gazzaniga, A., 2012. Injection Molding and its application to 420 
drug delivery. J. Control. Release doi:10.1016/j.jconrel.2012.01.001. 
Zhang, X., Wang, Y., Wang, J., Wang, Y., Li, S., 2007. Effect of pore former on the properties of casted film 
prepared from blends of Eudragit
®
 NE 30D and Eudragit
®
 L 30 D-55. Chem. Pharm. Bull. 55, 1261-1263. 
Zhang, Y., Brown, K., Siebenaler, K., Determan, A., Dohmeier, D., Hansen, K., 2012. Development of 
lidocaine-coated microneedle product for rapid, safe, and prolonged local analgesic action. Pharm. Res. 29, 425 
170-177. 
Zweifel, H., Maier, R.D., Schiller, M., (Eds.) 2009. Plastics additives handbook, sixth ed., Hanser, Ohio. 
Table 1 Composition (% by weight) of molded formulations 
 Polymer Plasticizer Release modifier 





PEG15 87 13 - - 
PEG25 80 20 - - 
PEG35 74 26 - - 
EXP 60 15 25 - 
EXPPEG35 55 20 25 - 
KIR 60 15 - 25 
1EXP2KIR 60 15 8.5 16.5 
2EXP1KIR 60 15 16.5 8.5 
 
Table 1
Table 2 IM operating conditions 




Plasticating chamber temperature (°C) 120-160 140-165 
Injecting temperature (°C) 130-170 143-168 
Nozzle temperature (°C) 140-180 145-170 
Charge (mm) 4.5-11 6-20 
First-injection pressure (bar) 20-90 60-110 
First-injection time (sec) 0.8 0.8-20 
First-injection rate (%) 40-90 5-85 
Second-injection pressure (bar) 15-70 35-65 
Second-injection time (sec) 0.3 0.3-10 
Second-injection rate (%) 30-70 40-75 
Cooling temperature (°C) 15 15-25 
Cooling pressure (bar) 60 60-90 
Cooling time (sec) 2.5 10 
Opening rate (%) 20-40 40 
 
Table 2





t = 0 t = 24 h t = 0 t = 3 h t = 24 h 
PEG 15 43 (7) 47 (8) 
   
PEG 25 55 (23) n.d. 
   
PEG 35 35 (21) n.d. 
   
n.d. = not determined because of disk deformation 
Table 3
Figure 1 Outline of the system for the evaluation of disk gastric resistance. 
 
Figure 2 Interrelated steps involved in the development of the molded device. 
 
Figure 3 Photomicrographs of the surface (a, b and c) and cross-section (at, bt and ct) of molded HPMCAS-
based 400µm disks, as such (a and at) or containing 30 % by weight of a release modifier (Kollicoat
®
 IR: b and bt 
or Explotab
®
 CLV: c and ct). 
 
Figure 4 Release profiles of 900 µm thick enteric capsular devices containing 30% by weight of a release 
modifier (top: Kollicoat
®
 IR, bottom: Explotab
®
 CLV); mean t10% (min) in pH 6.8 buffer and relevant CV 
highlighted in tables. 
 
Figure 5 Amount (%) of tracer in the acceptor fluid separated from the donor compartment by molded 
HPMCAS disks of differing thicknesses (600, 400 and 200 µm for a, b and c, respectively) containing 30% by 
weight of a release modifier (Kollicoat
®
 IR on the left and Explotab
®
 CLV on the right) vs time profiles; mean 
t10% (min) in pH 6.8 buffer and relevant CV highlighted in tables. 
 
Figure 6 Photomicrographs at different magnification (110, 400, 800, 2000 X for a, b, c, and c’, respectively) of 
the surface of HPMCAS-based 400µm disks containing 30 % of Explotab
®
 CLV after exposure to pH 6.8 buffer; 
c’ is a detail from photomicrograph c. 
 
Figure 7 Release profiles of 900 µm thick enteric capsular devices containing 30% by weight of a mixture of 
release modifiers (top: 10% Explotab
®
 CLV and 20 % Kollicoat
®
 IR, bottom: 20% Explotab
®
 CLV and 10 % 
Kollicoat
®
 IR); mean t10% (min) in pH 6.8 buffer and relevant CV highlighted in tables. 
 
Figure 8 Release profiles of 600 µm thick enteric capsular devices containing 30% by weight of Explotab
®
 
CLV; mean t10% (min) in pH 6.8 buffer and relevant CV highlighted in tables. 
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